Sustaining Innovation Analyst Day

IR thematic call on alirocumab

Sanofi and Regeneron hosted an IR Thematic Conference Call for the financial community focusing on alirocumab during the American College of Cardiology Annual Meeting.

Alirocumab (SAR236553/ REGN727) is an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) for the reduction of LDL-cholesterol. Alirocumab is currently being evaluated in a large Phase 3 program in patients with hypercholesterolemia.

This website uses cookies to track its audience and improve its content. By continuing to browse this website, you agree to the use of such cookies.

Click here for more information on cookies
OK